Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 87.73B | 77.6x | 0.04 | DKK 1,420.50 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 25.54B | -20.9x | 0.57 | DKK 359.20 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 6.62B | -228.7x | -7.71 | DKK 402.40 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 100.16M | -7.4x | -0.65 | DKK 12.95 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 44.21M | -132.1x | -1.5 | DKK 1,060 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |